These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 24142521)

  • 1. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.
    Lawrie TA; Rabbie R; Thoma C; Morrison J
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD010482. PubMed ID: 24142521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
    Lawrie TA; Bryant A; Cameron A; Gray E; Morrison J
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006910. PubMed ID: 23835762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
    Newhouse R; Nelissen E; El-Shakankery KH; Rogozińska E; Bain E; Veiga S; Morrison J
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD006910. PubMed ID: 37407274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
    Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials.
    Li XR; Zhu Y; Zhang GN; Huang JM; Pei LX
    J Ovarian Res; 2021 Mar; 14(1):42. PubMed ID: 33750444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
    Wuntakal R; Seshadri S; Montes A; Lane G
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy for advanced endometrial cancer.
    Galaal K; Al Moundhri M; Bryant A; Lopes AD; Lawrie TA
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD010681. PubMed ID: 24832785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.
    Pierre ME; Manneh R; Hernández A; Rodríguez J; Fletcher AV; Ramírez HM; Niño OM; Gómez DA; Sanabria D; Contreras F; Pieschacón JR; Calderón PH
    Rev Colomb Obstet Ginecol; 2024 Jun; 75(1):. PubMed ID: 39013199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials.
    Gibson JM; Alzghari S; Ahn C; Trantham H; La-Beck NM
    Oncologist; 2013; 18(9):1022-31. PubMed ID: 23881990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer.
    Ngoi NY; Syn NL; Goh RM; Goh BC; Huang RY; Soon YY; James E; Cook A; Clamp A; Tan DS
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD012007. PubMed ID: 35188221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
    Pignata S; Scambia G; Ferrandina G; Savarese A; Sorio R; Breda E; Gebbia V; Musso P; Frigerio L; Del Medico P; Lombardi AV; Febbraro A; Scollo P; Ferro A; Tamberi S; Brandes A; Ravaioli A; Valerio MR; Aitini E; Natale D; Scaltriti L; Greggi S; Pisano C; Lorusso D; Salutari V; Legge F; Di Maio M; Morabito A; Gallo C; Perrone F
    J Clin Oncol; 2011 Sep; 29(27):3628-35. PubMed ID: 21844495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancer.
    Lawal AO; Musekiwa A; Grobler L
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD009620. PubMed ID: 23740789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
    Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
    Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review.
    Holloway RW; Grendys EC; Lefebvre P; Vekeman F; McMeekin S
    Oncologist; 2010; 15(10):1073-82. PubMed ID: 20930103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
    Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Park YC; Parekh TV; Poveda AM
    Eur J Cancer; 2012 Oct; 48(15):2361-8. PubMed ID: 22541893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
    Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD
    Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
    Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of pegylated liposomal doxorubicin and paclitaxel plus carboplatin-based chemotherapy as first line treatment for patients with ovarian cancer: a systematic review and meta-analysis of randomized controlled trials.
    Shi SQ; Jiang FF; Hong T; Zhuang Y; Chen L; Huang XL
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):2911-2927. PubMed ID: 32271409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
    Gaitskell K; Rogozińska E; Platt S; Chen Y; Abd El Aziz M; Tattersall A; Morrison J
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007930. PubMed ID: 37185961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.